| Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. | |
| | |
MedLine Citation:
|
PMID: 20331602 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: Increased oxidative stress and up-regulation of matrix metalloproteinases (MMPs) may cause structural and functional vascular changes in renovascular hypertension. We examined whether treatment with spironolactone (SPRL), hydrochlorothiazide (HCTZ) or both drugs together modified hypertension-induced changes in arterial blood pressure, aortic remodelling, vascular reactivity, oxidative stress and MMP levels and activity, in a model of renovascular hypertension. EXPERIMENTAL APPROACH: We used the two-kidney,one-clip (2K1C) model of hypertension in Wistar rats. Sham-operated or hypertensive rats were treated with vehicle, SPRL (25 mg.kg(-1).day(-1)), HCTZ (20 mg.kg(-1).day(-1)) or a combination for 8 weeks. Systolic blood pressure was monitored weekly. Aortic rings were isolated to assess endothelium-dependent and -independent relaxations. Morphometry of the vascular wall was carried out in sections of aorta. Aortic NADPH oxidase activity and superoxide production were evaluated. Formation of reactive oxygen species was measured in plasma as thiobarbituric acid-reactive substances. Aortic MMP-2 levels and activity were determined by gelatin and in situ zymography, fluorimetry and immunohistochemistry. KEY RESULTS: Treatment with SPRL, HCTZ or the combination attenuated 2K1C-induced hypertension, and reversed the endothelial dysfunction in 2K1C rats. Both drugs or the combination reversed vascular aortic remodelling induced by hypertension, attenuated hypertension-induced increases in oxidative stress and reduced MMP-2 levels and activity. CONCLUSIONS AND IMPLICATIONS: SPRL or HCTZ, alone or combined, exerted antioxidant effects, and decreased renovascular hypertension-induced MMP-2 up-regulation, thus improving the vascular dysfunction and remodelling found in this model of hypertension. |
| | |
Authors:
|
C S Ceron; M M Castro; E Rizzi; M F Montenegro; V Fontana; M C O Salgado; R F Gerlach; J E Tanus-Santos |
Publication Detail:
|
Type: In Vitro; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-03-19 |
Journal Detail:
|
Title: British journal of pharmacology Volume: 160 ISSN: 1476-5381 ISO Abbreviation: Br. J. Pharmacol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-23 Completed Date: 2010-07-26 Revised Date: 2011-07-28 |
Medline Journal Info:
|
Nlm Unique ID: 7502536 Medline TA: Br J Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 77-87 Citation Subset: IM |
Affiliation:
|
Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antioxidants / pharmacology*, therapeutic use Aorta / drug effects, enzymology, physiopathology Blood Pressure / drug effects Drug Therapy, Combination Hydrochlorothiazide / pharmacology*, therapeutic use Hypertension, Renovascular / drug therapy, metabolism*, physiopathology Lipid Peroxides / metabolism Matrix Metalloproteinase 2 / metabolism* Muscle, Smooth, Vascular / drug effects, physiopathology Oxidative Stress / drug effects Rats Reactive Oxygen Species / metabolism Spironolactone / pharmacology*, therapeutic use Vasodilation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antioxidants; 0/Lipid Peroxides; 0/Reactive Oxygen Species; 52-01-7/Spironolactone; 58-93-5/Hydrochlorothiazide; EC 3.4.24.24/Matrix Metalloproteinase 2; EC 3.4.24.24/Mmp2 protein, rat |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Amitriptyline does not block the action of ATP at human P2X4 receptor.
Next Document: GSK3beta: role in therapeutic landscape and development of modulators.